Lung disorder

This phase 1 trial tests a new type of CAR-T cell therapy designed to target a protein called DLL3 found on small cell lung cancer cells. The CAR-T cells are also modified to boost their activity through PD-L1 and 4-1BB signals. The study enrolls adults with relapsed or refractor…

This trial is testing an updated version of the BNT162b2 COVID-19 vaccine in healthy adults aged 18 to 64. Participants will receive either the updated COVID-19 vaccine or a Tdap vaccine (for tetanus, diphtheria, and whooping cough) to compare safety and measure spike protein lev…

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This trial is testing whether combining two immunotherapy drugs, cemiplimab and dupilumab, can safely and effectively shrink tumors in people with early-stage, operable non-small cell lung cancer. Participants receive both drugs before their scheduled surgery, and researchers wil…

This study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …

This phase 2 trial tests whether galvokimig, an experimental biologic drug, can reduce the number of moderate-to-severe COPD flare-ups in people with chronic bronchitis. About 400 adults aged 40 to 80 with moderate-to-severe COPD will receive either galvokimig or a placebo as an …

This Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…

This Phase 2 trial tests the drug alisertib in 120 people with extensive stage small cell lung cancer that has worsened after standard treatments like chemotherapy and immunotherapy. The goal is to see if alisertib can shrink tumors or slow the disease, and to identify which pati…

This phase 3 trial tests whether adding a precise, high-dose radiation treatment (SBRT) to standard chemoradiation and immunotherapy improves survival for people with locally advanced non-small cell lung cancer that cannot be surgically removed. About 474 participants will be ran…

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

This phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This early-phase study tests gilteritinib, a drug already approved for a type of leukemia, in about 40 adults with ALK-positive non-small cell lung cancer whose tumors no longer respond to standard ALK inhibitors. Participants take gilteritinib tablets daily in 28-day cycles. The…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The trial has two parts: first checking safety, then comparing the new combo to an approved treatment (atezoli…

This phase III trial tests whether proton craniospinal irradiation (pCSI) can improve survival compared to standard involved-field radiation therapy (IFRT) for patients with breast or non-small cell lung cancer that has spread to the lining of the brain and spinal cord (leptomeni…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy and immunotherapy, for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 170 participants…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This study tests whether a new drug combination (BMS-986489) works better than the current standard (durvalumab) as follow-up treatment after chemoradiation for limited-stage small cell lung cancer. About 250 adults whose cancer hasn't spread widely will be randomly assigned to o…

This study tests personalized radiotherapy approaches for people with lung cancer, brain metastases, or other solid tumors. It aims to see if adapting radiation based on how a patient responds is safe and effective. About 45 adults will participate, receiving either extra radiati…

This early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…

This study compares an experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive one of the two drugs by …

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…

This phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…

This trial asks whether giving COPD medication through a nebulizer works better than a dry powder inhaler. It enrolls adults over 40 with COPD symptoms and significant air trapping. Participants receive either a nebulizer or inhaler treatment, and researchers compare changes in l…

This study tests whether opening blood vessels (vasodilation) or removing fluid (diuretics) is better for treating sudden fluid buildup in the lungs from heart failure. About 1,100 adults with severe shortness of breath and low oxygen levels will receive one of three treatments i…

This study is exploring whether giving radiotherapy at the same time as immunotherapy and chemotherapy, versus giving it after, works better as a first treatment for extensive-stage small cell lung cancer. The trial will enroll about 60 adults with this advanced cancer. Participa…

This study tests a new medicine called fosmanogepix for adults with serious mold infections that are hard to treat. About 234 people will join, receiving either the new drug or standard care. The main goal is to see if fewer people die by day 42. The study is currently recruiting…

This study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…

This study tests a new exercise approach for people with COPD, a lung disease that makes breathing hard. Researchers will compare standard pulmonary rehab with a version that uses a blood flow restriction cuff during low-intensity aerobic exercise. The goal is to see if this meth…

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops from another lung cancer type. About 40 participants will receive the drug combo through IV infusions…

This Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…

This study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This phase 2 trial is testing a type of radiation called craniospinal irradiation that avoids the hippocampus, a brain area key for memory. It is for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if …

This early-phase study tests a new drug called SV001 in 53 healthy Chinese adults to see if it is safe and how the body processes it. Participants receive a single dose of SV001 or a placebo. The goal is to check for side effects and measure drug levels in the blood. This is a fi…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…

This phase 3 trial tests a new antiviral pill, ibuzatrelvir, alone or with an IV drug (remdesivir) in 300 adults with weak immune systems who have mild-to-moderate COVID-19. The goal is to see if the combination prevents hospitalizations or worsening symptoms better than remdesiv…

This study tests a new drug called rilvegostomig against the standard drug pembrolizumab, both given with chemotherapy, as a first treatment for people with advanced non-squamous lung cancer that has spread. About 878 adults whose tumors have a specific protein (PD-L1) will take …

This study tests an oral medication called ibuzatrelvir in adults and teens with COVID-19 who are not hospitalized but have a high risk of becoming severely ill. Participants will receive either the drug or a placebo for 5 days, and researchers will track whether it reduces emerg…

This phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…

This study tests a new drug called telisotuzumab adizutecan (ABBV-400) combined with an immunotherapy drug (budigalimab or pembrolizumab) in people with advanced non-squamous lung cancer who have not had prior treatment. The goal is to find the best dose that is safe and effectiv…

This study looks at whether giving radiation to the chest after surgery and chemo-immunotherapy can help people with stage III non-small cell lung cancer who still have signs of cancer after treatment. About 118 adults will be randomly assigned to receive or not receive radiation…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after surgery can help prevent non-small cell lung cancer from coming back. About 1,210 people with stage II to IIIB lung cancer will receive either chemo plus pembrolizumab toge…

This study tests a stem cell transplant using the patient's own blood cells to treat severe scleroderma (systemic sclerosis) that hasn't improved with standard drugs. The goal is to see if this high-dose therapy is safe and can stop the disease from getting worse. The trial enrol…

This phase 2 trial is testing a combination of three drugs—datopotamab deruxtecan, carboplatin, and pembrolizumab—in 46 people with non-small cell lung cancer that has spread to the brain and who have not had prior treatment for those brain tumors. The goal is to see how well the…

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…

This phase 2 trial is testing three different doses of an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has high levels of a protein called c-Met and no EGFR mutation). The drug …

This phase 3 trial tests whether adding the targeted drug adagrasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 630 adults who have not had …

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…

This phase 3 trial tests an inhaled drug called treprostinil palmitil in 344 adults with pulmonary hypertension caused by interstitial lung disease. Participants take the drug or a placebo once daily for 24 weeks. The main goal is to see if the drug helps them walk farther in six…

This phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…

This study investigates whether inhaling the antibiotic amikacin can better treat pneumonia caused by gram-negative bacteria in patients on veno-arterial ECMO (a heart-lung bypass machine). Standard antibiotics often fail in these patients, possibly because the bypass reduces blo…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This phase II trial tests two drugs, lurbinectedin and avelumab, in people with a rare and aggressive bladder cancer called small cell carcinoma. Participants who have already had a drug like avelumab will receive only lurbinectedin; others will get both. The study aims to see if…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …

This Phase 2 trial tests an experimental inhaled medication called LTI-03 in about 120 people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes scarring and breathing difficulty. Participants will inhale LTI-03 or a placebo twice daily for 24 weeks.…

This study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is t…

This study tests whether a pulmonary rehabilitation program delivered via telehealth can help people with chronic obstructive pulmonary disease (COPD) recover after a hospital stay for a sudden worsening of their condition. Participants will join an eight-session remote program, …

This phase 2 trial is testing two experimental drugs, ubamatamab and REGN7075, alone or together, in 300 people with advanced or metastatic non-small cell lung cancer who have already had standard treatments. A third drug, sarilumab, may be used to manage immune-related side effe…

This phase 3 study tests the long-term safety of an inhaled drug called treprostinil palmitil for people with pulmonary hypertension caused by interstitial lung disease. About 344 adults who completed an earlier trial will take the drug for up to 2 years. Researchers will track s…

This early-stage study tests a new tablet, AST2303, in 120 people with advanced non-small cell lung cancer that has spread. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or slow the disease. Participants will take…

This trial tests whether taking firmonertinib after surgery can help prevent non-small cell lung cancer from coming back in people with certain uncommon EGFR mutations. Participants who had their tumor completely removed will receive either firmonertinib or a placebo daily. The s…

This study tests whether a new drug combo (sotorasib plus chemotherapy) works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has a specific KRAS G12C gene change and low PD-L1 levels. About 750 adults wh…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This phase 3 study compares two immunotherapy drugs—rilvegostomig and pembrolizumab (Keytruda)—each combined with standard chemotherapy, as a first treatment for people with advanced squamous non-small cell lung cancer that has a specific protein (PD-L1). About 880 participants w…

This pilot study explores whether a newer ventilation method called flow-controlled ventilation (FCV) can help intubated patients with asthma or COPD exacerbations breathe with less effort compared to standard volume-controlled ventilation (VCV). Ten adult patients on mechanical …

This early-phase trial is testing whether combining two experimental drugs, JAB-21822 and JAB-3312, can safely shrink or control advanced solid tumors that carry a specific KRAS G12C mutation. The study includes people with cancers like non-small cell lung, colorectal, or pancrea…

This Phase III trial is testing whether adding bevacizumab to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 300 people with stage IIIB or IV disease will be randomly assigned to receive either the combination or osimertini…

This trial is testing an oral drug called JAB-21822 in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation along with an STK11 mutation. The study aims to see if the drug is safe, tolerable, and effective in shrinking tumors. Partic…

This study takes white blood cells from a patient's lung tumor, grows them in large numbers in the lab, and gives them back to the patient to fight the cancer. The goal is to see if these specially selected cells can shrink tumors in people with advanced non-small cell lung cance…

This phase III trial compares adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in adults aged 70+ with advanced non-small cell lung cancer. The goal is to see if the combination improves survival. About 304 participants will be enrolled.

This study tests whether a new drug called furmonertinib, given with chemotherapy, works better than the current standard drug osimertinib for people with a specific type of lung cancer (EGFR-mutant non-squamous NSCLC) that has spread to the brain. About 380 adults whose cancer h…

This trial is testing whether the drug furmonertinib can help prevent non-small cell lung cancer from coming back after surgery. The study enrolls adults with stage II-IIIA lung cancer that has specific EGFR mutations and who have had the tumor completely removed, with or without…

This phase II trial tests whether a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced bronchial neuroendocrine tumors (a type of lung cancer). The radioactive drug targets a protein on tumor cells and delivers ra…

This phase 3 trial is investigating whether a combination of two oral drugs, JAB-21822 and JAB-3312, can work better than the current standard treatment (immunotherapy plus chemotherapy) as a first-line therapy for people with advanced non-squamous non-small cell lung cancer that…

This study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This trial tests whether a specific breathing exercise, the Buteyko technique, can improve oxygen levels, reduce breathlessness, and enhance exercise ability in patients with pneumonia caused by smog. It compares this approach to incentive spirometry, a standard device that encou…

This study compares the standard drug osimertinib alone versus osimertinib plus chemotherapy (carboplatin and pemetrexed) in people with metastatic EGFR-mutant lung cancer who still have detectable cancer DNA in their blood after starting osimertinib. The goal is to see if the co…

This trial tests an experimental oral drug called TT-702 in people with advanced solid tumors. The drug works by blocking a protein that tumors use to hide from the immune system. The study aims to find the safest dose of TT-702 when given alone and in combination with an immunot…

This study tests whether adding a new drug called cirtuvivint to standard chemotherapy can help people with small cell lung cancer that has come back after initial treatment. About 42 adults whose cancer has progressed after at least one prior therapy will receive the combination…

This trial tests whether starting respiratory physiotherapy within one hour of breathing tube removal after elective coronary artery bypass surgery improves lung function and reduces complications compared to waiting until the next day. Forty adults undergoing planned heart surge…

This phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) helps people with extensive stage small cell lung cancer live longer compared to standard treatments. About 695 participants who have already had one round of chemotherapy will be randomly assigned to rece…

This Phase 3 trial is testing whether a combination of two drugs, datopotamab deruxtecan (Dato-DXd) and rilvegostomig, works better than the current standard treatment pembrolizumab for people with advanced non-squamous lung cancer that has high PD-L1 levels. About 675 participan…

This study tests a breathing machine strategy that adjusts pressure based on lung measurements to protect the right side of the heart in 180 adults with moderate to severe lung failure from pneumonia. The goal is to see if this method reduces heart strain and complications compar…

This study tests a new drug called GSK3862995B in 446 adults with bronchiectasis, a long-term lung condition. The goal is to see if the drug can reduce the number of serious lung infections (exacerbations) compared to a placebo. Participants will receive either one of two doses o…

This trial is testing whether adding radiation to the chest can help people with extensive-stage small-cell lung cancer, a type of lung cancer that has spread widely. Participants first receive standard chemotherapy plus an immunotherapy drug, and if their cancer does not worsen,…

This phase II trial is testing whether a combination of two drugs, SKB264 and SKB118, can safely shrink tumors in people with advanced non-small cell lung cancer that has spread. The study includes a dose-finding phase and an expansion phase to better understand the treatment's e…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This study tests a new oral drug, BAY 2927088, for people with advanced non-small cell lung cancer that has specific EGFR or HER2 mutations. The trial has four parts to find the safest dose and see if the drug shrinks tumors. About 400 participants will take the drug daily until …

This trial is for people with extensive-stage small cell lung cancer who have completed initial chemotherapy plus immunotherapy and have stable or improved disease. Participants are randomly assigned to receive either standard immunotherapy alone or immunotherapy combined with in…

This trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study tests a new way to give Alpha1-Proteinase Inhibitor—a medicine that helps protect the lungs in people with Alpha-1 Antitrypsin Deficiency. Instead of getting it through a vein at a clinic, participants will receive it as a weekly injection under the skin. The trial wil…

This study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…

This study tests an experimental tablet called AZD6793 in adults with moderate to very severe COPD. About 987 participants will take one of two doses of the drug or a placebo for 24 weeks. The goal is to see if the drug can reduce the number of serious flare-ups (exacerbations) c…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This early-phase study tests whether combining valemetostat with atezolizumab is safe as maintenance therapy for people with extensive-stage small cell lung cancer. Researchers will try different doses of valemetostat to find the best one with few side effects. The study involves…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-stage trial tests whether inhaling small mobile stem cells (SMS) is safe for people with mild to moderate COPD. 18 participants aged 39–69 will receive the cells via a nebulizer. The study focuses on safety and side effects, not yet on whether the treatment works.

This phase 2 trial is testing whether an experimental biologic drug called galvokimig can delay the first moderate or severe lung infection (pulmonary exacerbation) in adults with non-cystic fibrosis bronchiectasis, a chronic lung condition that causes coughing, mucus buildup, an…

This study tests a new combination of two drugs—gemcitabine (chemotherapy) and ivonescimab (a targeted therapy)—in people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy. The goal is to see if this combination can shrink tumors or sto…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-phase trial is testing a combination of two drugs—izalontamab brengitecan (given by IV) and adagrasib (a pill)—in 18 adults with advanced KRAS G12C-mutant non-small cell lung cancer that has stopped responding to other treatments. The main goal is to check safety and s…

This study tests different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. The drugs are chosen based on specific genetic markers in each person's tumor. The goal is to see if these treatments shrink the tumor before surge…

This study tests whether giving immunotherapy (Cemiplimab) along with chemotherapy (Carboplatin and Paclitaxel) before radiation can help elderly or unfit patients with stage III non-small cell lung cancer live longer without their cancer getting worse. The trial will enroll 152 …

This early-stage trial tests whether artesunate, a drug used for malaria, is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Fifteen adults with IPF will receive either artesunate capsules or a placebo for 12 week…

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

This early-phase study tests a new drug called HLX3902 in about 48 people with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. The drug is designed to help the …

This trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…

This phase 3 trial tests a new daily pill, GFH375, against standard chemotherapy (docetaxel) in 300 people with advanced KRAS G12D lung cancer that has worsened after prior treatments. The drug is designed to block the specific cancer-driving mutation. Participants are randomly a…

This phase 3 study compares the experimental drug pumitamig to the standard treatment durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have finished chemoradiation without their cancer getting worse. The main goal is to see if p…

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This study tests whether adding the experimental drug visugromab to standard chemotherapy and immunotherapy can shrink tumors better than standard treatment alone in people with advanced non-squamous lung cancer that has not been treated before. About 107 adults with newly diagno…

This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…

This study tests a new combination of two drugs, AMT116 and ivosimab, in people with advanced non-small cell lung cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination shrinks tumors. About 118 adults aged 18 to 75 will take part…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This trial is testing whether giving a combination of oral paclitaxel (a chemotherapy pill), an immunotherapy drug, and focused radiation before surgery can help older adults with stage IIA-IIIB non-small cell lung cancer. The goal is to see if this pre-surgery treatment can shri…

This study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This phase 3 trial compares a new drug called pumitamig to the standard drug pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1 (at least 50%). The study will enroll 750 participants and measure ho…

This study tests an inhaled version of the drug nintedanib (called AP02) in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 160 adults aged 40 and older who are not currently on IPF treatment will take either a low o…

This study tests a new drug called volrustomig combined with other cancer treatments for people with advanced non-small cell lung cancer. The main goals are to check safety and see if tumors shrink. About 180 adults will take part in this early-stage trial.

This study looks at whether non-small cell lung cancer patients who are less fit (performance status 2) can be treated just as effectively with a combination of chemotherapy and immunotherapy as those who are more fit (performance status 0-1). About 105 participants will receive …

This study tests whether the drug belumosudil can prevent chronic lung allograft dysfunction (CLAD) in people who have had a lung transplant and show signs of rejection or inflammation on a biopsy. About 234 participants will receive either belumosudil or a placebo for 52 weeks, …

This study tests whether adding a new drug called navlimetostat to standard immunotherapy (pembrolizumab) and chemotherapy helps people with a specific genetic form of advanced lung cancer (MTAP deletion) live longer without their cancer worsening. About 590 participants will be …

This study tests whether adding radiation therapy to the usual maintenance drug atezolizumab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 138 participants who have already responded to initial chemo-immunotherapy will be…

This early-stage trial is testing an experimental drug called MK-4716, alone or combined with other cancer drugs, in people with advanced solid tumors that have a KRAS mutation. The main goal is to see if the drug is safe and tolerable. About 250 participants will be enrolled.

This study tests a drug called vadadustat in 1,100 hospitalized adults with acute respiratory distress syndrome (ARDS) caused by infection. Participants take either a low or high dose of vadadustat or a placebo daily for up to 14 days. The goal is to see if the drug reduces death…

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …

This study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …

This early-stage trial tests an experimental pill called JBI-778 in people with certain advanced cancers: EGFR-mutated lung cancer (with or without brain metastases), recurrent high-grade glioma, or adenoid cystic carcinoma. The drug is designed to block a protein that helps canc…

This phase 2 trial tests an oral drug called PIPE-791 in 324 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either a low or high dose of PIPE-791 or a placebo daily for several months. The main goal is t…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This phase II trial tests whether adding local treatments like surgery or radiation to the immunotherapy drug durvalumab can help control stage III non-small cell lung cancer that has progressed after chemoradiation and durvalumab. About 51 participants with 3 or more growing tum…

This study tests an experimental oral drug called ROC-101 in 40 adults with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (ILD-PH). Participants take the drug alongside their standard care for 24 weeks, with a long-term follow…

This phase 2 trial tests whether MTX-463, an antibody that blocks a protein linked to scarring, can slow lung function decline in people with idiopathic pulmonary fibrosis (IPF). About 164 adults with IPF will receive either the drug or a placebo for 24 weeks. The main goal is to…

This phase III trial is investigating whether surgically removing the primary lung tumor, in addition to continuing the targeted therapy osimertinib, can prolong the time before disease progression in patients with EGFR-mutant non-small cell lung cancer that has spread to a limit…

This study looks at the long-term safety of an inhaled drug (AP01) for people with progressive lung scarring (pulmonary fibrosis). It is for those who already completed an earlier Avalyn Pharma study. About 340 participants will receive the drug and be monitored for side effects …

This trial is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis) and has stopped responding to third-generation targeted pills. The study tests whether a pe…

This trial tests whether a smartphone app, paired with a wireless spirometer, can help people with asthma or COPD use their inhalers correctly. Participants are randomly assigned to either standard inhaler education or app-based training that measures their inhalation flow and pr…

This study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer…

This study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…

This early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and se…

This study is testing a device called the Indigo Aspiration System to remove blood clots from leg arteries in people with acute limb ischemia, a condition where a clot suddenly blocks blood flow. About 300 participants will undergo a procedure where the device sucks out the clot.…

This trial tests whether a device that sends gentle vibrations through the chest can help people with COPD cough up more sputum (mucus) during a standard collection procedure. Each participant undergoes the procedure twice—once with the device and once without—to compare the amou…

This study looks at how safe and effective the antibiotic lefamulin is for treating community-acquired pneumonia (CAP) in Chinese patients. CAP is a lung infection caught outside of hospitals, and many common antibiotics are becoming less effective due to drug resistance. Lefamul…

This trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…

This early-phase trial is testing whether combining two experimental drugs, tarlatamab and ZL-1310, with or without the immunotherapy durvalumab, can safely shrink tumors in people with small cell lung cancer that has worsened after standard treatment. About 160 adults will take …

This Phase 2 study tests whether a once-daily oral tablet called EXPD-101 can reduce the number of moderate to severe COPD flare-ups in people with chronic bronchitis. Participants must have had at least two moderate or one severe exacerbation in the past year. The trial compares…

This Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…

This study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…

This Phase 3 study tests whether adding olomorasib (a targeted pill) to standard immunotherapy (pembrolizumab or durvalumab) works better than immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer. The trial has two parts: one for patients whose cancer w…

This trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…

This program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This trial tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer from growing. About 45 adults whose cancer responded to initial chemo-immunotherapy will receive the combi…

This study tests whether taking pentoxifylline and vitamin E during chemoradiation can prevent lung injury (pneumonitis) in stage III non-small cell lung cancer patients. 150 participants will receive either the drug combo or a placebo for 6 months. The goal is to see if this red…

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…

This study tests a temporary device that stimulates the diaphragm (the main breathing muscle) in ICU patients on breathing machines. The goal is to see if it helps patients breathe more on their own and recover from lung injury. About 30 adults with severe breathing failure will …

This early-phase trial tests an experimental drug called D3S-002, taken as a daily pill, in adults with advanced solid tumors that have MAPK pathway mutations. The study has two parts: first, finding a safe dose, and second, testing that dose alone or with another drug (D3S-001) …

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This study follows 800 Chinese patients with early-stage ALK-positive non-small-cell lung cancer who took alectinib after surgery to see how long they stay cancer-free. Researchers will collect real-world data on disease-free survival and patient characteristics. The goal is to u…

This study tests the long-term safety of the drug nerandomilast in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). All 1,700 participants have already taken the drug in a previous study. They will take nerandomilast tablets for up to 1 yea…

This study tests a new targeted therapy called MK-1084, alone or combined with other drugs, in 190 people with advanced non-squamous non-small cell lung cancer that has a specific KRAS G12C mutation and has worsened after prior treatments. The main goals are to check safety and s…

This early-phase trial tests whether adding carotuximab to the standard drug osimertinib is safe for people with advanced EGFR-mutated non-small cell lung cancer. About 60 participants whose cancer has progressed on prior treatments will receive both drugs. The main goal is to fi…

This study tests a daily pill called BI 1291583 (Verducatib) in 1755 adults and teens with bronchiectasis, a lung condition causing frequent infections and coughing. Participants take either the drug or a placebo for up to 76 weeks. The main goal is to see if the drug reduces the…

This study tests whether adding an experimental drug (EIK1001) to standard immunotherapy and chemotherapy helps people with stage 4 non-small cell lung cancer live longer or slow tumor growth. About 750 adults whose cancer has spread will receive either the new combination or a p…

This program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This trial investigates whether placing infants with severe acute respiratory distress syndrome (ARDS) on their stomachs (prone positioning) after surfactant treatment can improve their oxygen levels. The study involves 14 mechanically ventilated infants, comparing oxygenation an…

This trial tests whether giving surfactant through a small tube while babies breathe with high-flow nasal cannula support can reduce the need for invasive ventilation. The study includes infants born 2-6 weeks early who have respiratory distress. Researchers will compare outcomes…

This study tests an inhaled drug called ensifentrine in 284 adults with non-cystic fibrosis bronchiectasis, a lung condition that causes frequent infections and breathing problems. Participants will receive either the drug or a placebo twice daily for at least 24 weeks. The goal …

This Phase 3 trial is testing a new oral drug called daraxonrasib (RMC-6236) against the standard chemotherapy docetaxel in about 590 people with advanced non-small cell lung cancer that has a specific RAS mutation. Participants must have already tried at least one prior treatmen…

This early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) against standard treatments for people whose small cell lung cancer has returned. About 540 adults with advanced disease will be randomly assigned to receive either I-DXd or a treatment chosen by their doctor. The g…

This Phase 3 trial tests a new inhaled medication called APC-0101 in 520 premature babies born between 26 and 33 weeks who have respiratory distress syndrome. The drug is a surfactant that helps keep tiny air sacs in the lungs open. Some babies receive the active drug through a s…

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This study tests whether a new drug (divarasib) combined with immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 600 adults who have not had…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…

This study tests whether adding a precise type of radiation therapy (I²-PORT) after lung cancer surgery can help prevent the cancer from coming back. Participants have non-small cell lung cancer with remaining cancer in lymph nodes after initial treatment. The trial compares stan…

This study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…

This phase 2 trial tests whether giving chemotherapy plus the immunotherapy drug cemiplimab (Libtayo) before surgery can shrink tumors enough to allow surgical removal in people with stage 3 non-small cell lung cancer that has spread to certain lymph nodes (N3). About 21 particip…

This program allows doctors to request NanO₂, an investigational drug that may help deliver oxygen to tissues, for patients with serious or life-threatening conditions like glioblastoma, respiratory distress, or ischemic stroke. It is for patients who have exhausted other treatme…

This Phase 3 trial tests an inhaled drug called ARINA-1 in 100 people who have had a double lung transplant and are showing early signs of lung function loss. The goal is to see if adding ARINA-1 to standard care can prevent further decline in lung function and improve quality of…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study tests two experimental drugs, BNT326 and BNT327, in people with advanced non-small cell lung cancer that has spread or come back. The trial has three parts to find the best dose and check safety, and will compare the combination to standard treatments like pembrolizuma…

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This phase II trial tests whether adding two types of precisely targeted radiation (BgRT and SBRT) to the standard drug osimertinib can better control advanced EGFR-positive lung cancer that has started to grow in a few new spots. About 32 adults with this specific type of lung c…

This study tests a new drug, BH-30643, in adults with advanced non-small cell lung cancer that has certain gene changes (EGFR or HER2 mutations). The goal is to find a safe dose and see if the drug can shrink tumors. About 266 people will take part across multiple locations.

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This phase II trial tests a new treatment for non-small cell lung cancer using immune cells taken from the patient's own tumor. The cells are grown in a lab and then infused back to attack the cancer. The study will enroll 28 adults and measure how well the treatment shrinks tumo…

This Phase 2 trial tests whether a new drug called EL219 (Turletricin) is safe and effective for early treatment of invasive mould infections in people with weakened immune systems, such as those who have had a bone marrow transplant. About 60 participants will receive either EL2…

This early-stage trial tests a personalized treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard treatments. The therapy uses immune cells taken from the patient's own tumor, multiplied in a lab, and then infused back i…

This trial tests whether aerobic exercise or resistance exercise can improve lung function in male quarry workers who have breathing problems from years of dust exposure. Participants will be randomly assigned to one of three groups: aerobic training, resistance training, or a co…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This trial asks whether giving sintilimab, an immune checkpoint inhibitor, after complete surgical removal of non-small cell lung cancer can improve outcomes for patients at high risk of recurrence. Participants who already received chemotherapy plus an immune checkpoint inhibito…

This phase III trial is testing whether giving chemotherapy and immunotherapy both before and after surgery (perioperative) is better than giving it only after surgery (adjuvant) for people with stage II-IIIB non-small cell lung cancer that can be removed. About 1,100 participant…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This study tests a new drug called ASP3082 in 60 people with advanced lung or pancreatic cancer that has a specific gene change (KRAS G12D). Participants receive the drug intravenously once a week in 21-day cycles. The main goal is to see how well the drug shrinks tumors and to u…

This phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This study tests the drug cabozantinib in people with advanced non-small cell lung cancer whose tumors have certain gene changes (RET, ROS1, NTRK fusions or increased MET/AXL activity). The drug is taken by mouth and aims to shrink tumors and stop them from growing. About 86 part…

This study tests a new drug called Rina-S in about 240 people with advanced non-small cell lung cancer. The goal is to see if the drug can shrink tumors or slow cancer growth. All participants receive the active drug, and treatment may continue as long as it helps and side effect…

This early-stage trial is testing whether a combination of two natural substances, deoxycytidine and deoxythymidine, is safe for people with telomere biology disorders. These rare genetic conditions cause premature aging, bone marrow failure, and lung scarring. Up to 36 participa…

This study tests a medicine called nerandomilast in children aged 2 to 17 with fibrosing interstitial lung disease, a condition where lung tissue becomes scarred and stiff. The goal is to see if the drug is safe and how the body processes it, and to get early signs of whether it …

This study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The …

This phase 3 trial tests TAK-928, a drug designed to activate T cells inside tumors, against standard chemotherapy (docetaxel) in 600 adults with advanced non-small cell lung cancer that has worsened after prior treatments. The goal is to see if TAK-928 can shrink tumors or help …

This trial is testing a new type of cell therapy for adults with small cell lung cancer that has returned or not responded to standard treatments. The therapy uses immune cells called natural killer (NK) cells, engineered to recognize and attack cancer cells through two targets a…

This study tests a new targeted drug called zongertinib, which blocks the HER2 protein that fuels cancer growth, in combination with standard chemotherapy (with or without the immunotherapy pembrolizumab). It is for people with advanced or metastatic non-squamous non-small cell l…

This trial is testing whether a pill form of the chemotherapy drug paclitaxel, taken alongside an immune checkpoint inhibitor, can help people with advanced lung cancer stay stable longer after their first round of treatment. The study includes two groups: one with squamous non-s…

This early-phase study tests whether adding an experimental drug (DSP-0390) to the immunotherapy atezolizumab can safely help prevent extensive stage small cell lung cancer from growing back after initial chemotherapy and immunotherapy. About 20 adults whose cancer did not worsen…

This early-stage study tests a new drug called XmAb819 in people with advanced clear cell kidney cancer that has come back or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 307 participants will receive the drug int…

This study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This study tests whether adding a new drug called BL-B01D1 to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that can be removed with surgery. About 90 participants will recei…

This Phase 2 trial tests an inhaled drug called LAM-001 (sirolimus) in 85 adults who have pulmonary hypertension (high blood pressure in the lungs) along with interstitial lung disease (lung scarring). The study compares the drug to a placebo to see if it improves blood flow in t…

This phase 2 trial is testing whether adding a targeted therapy called fumetinib to chemotherapy before standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that has EGFR mutations and cannot be removed by surgery. Participants are ran…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This trial tests whether a short course of exercise before lung cancer surgery can improve patients' fitness and post-operative outcomes. Participants with moderate-to-high surgical risk will be randomly assigned to either moderate-intensity continuous training or high-intensity …

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This phase 3 study compares a new biologic drug, rilvegostomig, to the standard drug pembrolizumab (Keytruda) as a first treatment for people with advanced non-small cell lung cancer that has high PD-L1 levels. About 830 participants worldwide will receive either drug by IV every…

This study tests whether fecal microbiota transplantation (FMT) — transferring healthy donor stool into the gut — can lower the risk of death in ventilated ICU patients with multidrug-resistant lung infections. The idea is that restoring gut bacteria may help fight lung infection…

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…

This trial tests whether an antibody called IC14 can reduce dangerous lung inflammation in people with acute respiratory distress syndrome (ARDS), a severe condition where the lungs fill with fluid. Hospitalized patients on a ventilator receive either IC14 or a placebo, and resea…

This trial is testing an experimental drug called petosemtamab (MCLA-158) in people with advanced solid tumors, including colorectal, head and neck, and lung cancers. The drug is a bispecific antibody designed to block two cancer-related proteins, EGFR and LGR5. Researchers want …

This trial tests whether operating on just one lung works as well as operating on both lungs for people with severe COPD and emphysema. The goal is to see if a less invasive approach can improve lung function with fewer risks. About 146 participants will be randomly assigned to o…

This early-phase trial is testing whether a stem cell therapy called REGEND001 can safely repair damaged lung tissue in adults with bronchiectasis, a chronic lung condition. The treatment uses a patient's own regenerative lung cells, which are collected, multiplied in a lab, and …

This early study tests a new stem cell therapy called REGEND001 for people with interstitial lung disease (ILD), a group of conditions that scar the lungs and make breathing difficult. The treatment uses a patient's own regenerative cells, collected from the airways during a scop…

This early-stage trial tests an inhaled drug called Rev-56 in healthy volunteers and in people with non-cystic fibrosis bronchiectasis who have chronic Pseudomonas aeruginosa lung infections. The study checks whether the drug is safe and how the body processes it, comparing Rev-5…

This phase 3 trial is testing whether adding one or two immune-boosting antibodies—toripalimab alone or combined with tifcemalimab—after standard chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without the cancer growing. About 756 particip…

This trial studies adults with moderate-to-severe acute respiratory distress syndrome (ARDS) who need ECMO life support. Researchers aim to classify patients into immune-based subtypes, understand why complications like kidney injury and bleeding occur, and develop a personalized…

This study investigates whether a standardized, full-course management pathway for ECMO can improve outcomes for adults with moderate-to-severe acute respiratory distress syndrome (ARDS). The pathway covers everything from deciding when to start ECMO through weaning and follow-up…

This trial tests whether digital inhaler coaching (DITM) and inspiratory muscle training (IMT), alone or together, can reduce serious flare-ups and hospitalizations in adults with symptomatic, high-risk COPD. Around 410 participants will be split into four groups: DITM, IMT, both…

This trial tests whether a device that sends mild electrical pulses to the spinal cord can help people with a cervical spinal cord injury breathe more independently. Twenty adults with a C1-C5 injury who need a ventilator will have electrodes implanted near the injury site and re…

This trial is testing an experimental drug called BL-M07D1 in people with a specific type of advanced non-small cell lung cancer that has a HER2 mutation. The study aims to find the best dose and see how well the drug shrinks tumors, while also checking for side effects. Particip…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-phase trial is testing an experimental oral drug called APG-2449 in people with advanced solid tumors, including certain lung cancers, mesothelioma, esophageal cancer, and ovarian cancer. APG-2449 is designed to block several proteins (FAK, ALK, and ROS1) that help can…

This trial tests whether a type of minimally invasive lung surgery that avoids inserting a breathing tube (non-intubated thoracoscopic surgery) can reduce complications in patients with impaired lung function. These patients often need ICU care after standard surgery because thei…

This phase II trial is testing whether combining an experimental drug called BL-B01D1 with a PD-1 monoclonal antibody can shrink tumors in people with extensive-stage small cell lung cancer. The study enrolls 66 adults aged 18 to 75 who have newly diagnosed, advanced disease. Res…

This early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…

This trial tests whether combining two drugs—dupilumab and cemiplimab—given before surgery can improve outcomes for people with early-stage non-small cell lung cancer. Participants receive one dose of each drug, then undergo standard surgery about two weeks later. Researchers mon…

This study tests whether digital tools—text messages, a chatbot, an educational video, and patient navigation—can help more people in low-resource clinics get screened for lung cancer. Participants are current or former smokers aged 50–80 who speak English or Spanish and have a p…

This study tests an experimental therapy called REGEND001 for people with moderate to severe COPD. The treatment uses a patient's own lung stem cells, collected via a bronchial brush, grown in a lab, and then infused back into the lungs. The goal is to see if it can safely improv…

This study compares two different schedules of stereotactic body radiotherapy (SBRT) for people with early-stage non-small-cell lung cancer. Patients are randomly assigned to receive radiation over 3 days or 5 days. The main goal is to see if one schedule causes fewer severe side…

This trial tests four different methods for setting the flow rate of a high-flow nasal cannula (a device that delivers warm, moist oxygen) after a breathing tube is removed. The goal is to find which approach best prevents the need for additional breathing support or re-intubatio…

This trial investigates whether different doses and durations of the corticosteroid dexamethasone improve outcomes for adults with acute respiratory distress syndrome (ARDS) who are on a ventilator. Participants are randomly assigned to receive either no steroids, a low or medium…

This trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…

This first-in-human trial tests an experimental drug called CTX-187 for safety and tolerability. It starts with healthy volunteers to assess single and multiple doses, then moves to patients with bronchiectasis who have a chronic Pseudomonas infection. The goal is to see if the d…

This study tests a new radioactive tracer called 18F-FAPI-74 that may help detect scar tissue (fibrosis) in the heart and lungs earlier than current methods. Researchers will compare this new PET/CT scan to standard imaging in 210 adults with conditions like lung disease or heart…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This early-phase trial tests whether a PET/CT scan using an investigational tracer called zirconium Zr 89 crefmirlimab berdoxam can safely and effectively spot CD8+ T cells—key immune cells that attack cancer—in people with metastatic non-small cell lung cancer. Participants are …

This trial is testing whether advanced PET-CT scans can spot early signs of heart damage caused by standard radiation therapy for locally advanced non-small cell lung cancer. Ten adults with stage III lung cancer will receive a special PET-CT scan before and three months after th…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This study tests a new radioactive tracer called 89Zr-DFO-SC16.56 that attaches to a protein called DLL3 found on small cell lung cancer cells. The goal is to see if PET scans using this tracer can safely and accurately show where the cancer is in the body. About 53 adults with s…

This trial is developing an AI-powered device that listens to children's heart, breath, and bowel sounds to identify signs of common diseases like congenital heart disease, bronchopneumonia, and abdominal issues. It will involve 30,000 children aged 0-18, some with these conditio…

This study is exploring whether artificial intelligence can analyze eye images to help diagnose lung diseases. Researchers will collect eye and lung examination data from 10,000 people with and without pulmonary conditions. By comparing the two, they aim to see if eye scans could…

This study evaluates whether an AI software called AccuPulmo CT Portal can accurately detect pulmonary fibrosis, a type of lung scarring, on chest CT scans. Researchers will compare the AI's readings against assessments by three lung specialists using 900 past scans. The goal is …

This study is testing a new device called a nitride-based Raman biochip that analyzes blood samples using light to detect molecular patterns linked to lung cancer. Researchers will compare results from 2,000 people with lung cancer and 1,000 without to see if the test can accurat…

This trial is testing whether a radiolabelled version of the drug patritumab deruxtecan (HER3-DXd) can be used as a PET imaging tracer to visualize HER3 protein throughout the body in people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the best imagin…

This study tests whether advanced imaging techniques, including oxygen-enhanced MRI and hyperpolarized xenon MRI, can detect chronic lung allograft dysfunction (CLAD) earlier than standard lung function tests. CLAD is a common complication after lung transplantation that can lead…

This study tests whether an artificial intelligence (AI) tool that analyzes a simple ECG can help doctors find undiagnosed pulmonary hypertension (high blood pressure in the lungs) in people with interstitial lung disease. About 900 adults with severe lung scarring will be random…

This study is testing a lung cancer screening program for smokers aged 45 to 74. It uses low-dose CT scans and metabolomics to find lung nodules and reduce false negatives. The goal is to improve early detection and help smokers quit. 1,000 participants will be followed in a publ…

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This trial is investigating whether a new radioactive tracer called 18F-grazy-02, used with PET/CT scans, can safely and effectively monitor how well immunotherapy is working in people with lymphoma or solid tumors. The tracer targets granzyme B, a protein released by immune cell…

This trial tests an artificial intelligence platform called NodeAI that analyzes ultrasound images in real time during a lung cancer staging procedure. The goal is to see if the AI can predict whether lymph nodes contain cancer more accurately than a surgeon's visual assessment. …

This study is testing whether a blood test that looks for specific chemical changes on DNA can help diagnose lung cancer. Researchers will collect blood samples from 750 adults, including those with lung cancer, precancerous conditions, and healthy volunteers, and analyze the DNA…

This study tests whether a non-invasive breathing test called Forced Oscillation Technique (FOT) can detect bronchiolitis obliterans syndrome (BOS) — a serious lung condition — earlier than standard tests in people who have received a bone marrow transplant. Researchers will comp…

This study is testing whether a blood test that looks for bits of tumor DNA (called ctDNA) can predict how well people with early-stage lung cancer respond to treatment. Researchers want to see if the test can identify patients who have no cancer left after chemotherapy and immun…

This study explores whether a biosensor using trained laboratory animals can detect non-small cell lung cancer (NSCLC) by smelling unique chemicals in urine. Participants include people with and without NSCLC, as well as those suspected of having it. The goal is to see if this an…

This study tests whether a special type of chest X-ray, called dynamic chest radiography, can help diagnose chronic obstructive pulmonary disease (COPD). Currently, COPD is diagnosed with lung function tests that require strong patient effort and may not be possible during a resp…

This Phase 1 trial tests a new radioactive tracer called [18F]-Fluorocellobiose ([18F]FCB) for PET/CT scans. The goal is to see if it can help find invasive mold infections in the body. The study includes healthy volunteers and people with known fungal infections. Participants re…

This study tests whether a prenatal education program can help pregnant women learn about and avoid toxic chemicals found in contaminated seafood. The program teaches about seafood benefits, risks, and safe handling. Researchers will measure changes in knowledge and whether women…

This study tests a drug called nerandomilast in 80 people aged 40+ who have early lung changes and a family history of pulmonary fibrosis. Participants take either the drug or a placebo twice daily for up to 3 years. Doctors monitor lung function and scans to see if the drug slow…

This study compares two flu vaccines—Fluad and Fluzone High-Dose—in adults aged 65 and older to see which is more effective at preventing lab-confirmed flu and related complications like pneumonia or heart issues. Researchers will look at health records from over a million senior…

This trial tests whether a mobile app called Wellnuts can help healthy adults aged 25–65 in Hong Kong become more aware of their health risks and take action. Participants use the app to assess their risk for conditions like diabetes, heart disease, and certain cancers, and recei…

This trial tests whether adding acupoint application—a herbal plaster placed on specific body points—to a standard anti-nausea drug can better control nausea and vomiting caused by chemotherapy in adults with lung cancer. Participants receiving first-line platinum-based chemother…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This study tests an investigational drug called CSL889 in 70 adults and adolescents with sickle cell disease who are having a painful vaso-occlusive crisis. The goal is to see if the drug can safely shorten the crisis and reduce the need for strong pain medicines. Participants wi…

This phase II trial tests whether esomeprazole, a common acid-reducing drug, can lower the chance of severe esophagitis (inflammation of the food pipe) in people with stage III non-small cell lung cancer receiving radiation therapy. Participants take 40 mg of esomeprazole daily d…

This trial tests whether a group balance training program called Sport4Steadiness (S4S) is acceptable and feasible for people with COPD who have balance problems or fear of falling. The program adapts sports and games into fun balance exercises, held twice a week for six weeks. R…

This study tests whether adding a special breathing treatment called intrapulmonary percussive ventilation (IPV) to standard care helps patients with pneumonia who are on a breathing machine. About 96 adults will be randomly assigned to receive either standard therapy alone or st…

This study tests an oral drug called vapendavir in 180 adults with COPD who catch a rhinovirus (common cold). The goal is to see if it can reduce the severity and length of breathing symptoms compared to a placebo. Participants are randomly assigned to one of two doses or a place…

This study tests whether adding lymphatic pump osteopathic manipulative therapy (OMT) to standard care helps older adults recover faster from respiratory illnesses like bronchitis, sinusitis, or pneumonia. Participants aged 65 to 100 with a new respiratory diagnosis will receive …

This study tests if a special high-flow oxygen mask works better than standard oxygen for people with high-altitude pulmonary edema (fluid in the lungs from climbing too high too fast). About 200 adults who develop symptoms within 7 days of reaching high altitude will be randomly…

This study tests whether acupressure can reduce coughing and related symptoms like shortness of breath and fatigue in lung cancer survivors. Eighty participants will either perform acupressure for 8 weeks or receive an educational booklet. Researchers will track changes in cough …

This study tests whether a CPAP device can reduce tumor movement in lung cancer patients during stereotactic body radiation therapy (SBRT). About 30 participants will use CPAP or deep inspiration breath hold to see which better stabilizes tumors. The goal is to improve treatment …

This study looks at whether 12 weeks of different exercise programs can help people with advanced lung cancer who are already receiving immunotherapy. The goal is to see if exercise is safe and doable, and if it can improve immune markers. About 30 adults with non-small cell lung…

This study compares two methods of giving surfactant, a medicine that helps premature babies breathe. One method uses a thin tube, the other uses a small airway device. The goal is to see which method causes fewer breathing problems and complications in infants born at 29 weeks o…

This pilot study tests a care model called Patient Priorities Care (PPC) for older African Americans with heart disease plus other chronic conditions like diabetes or COPD. The approach shifts focus from treating each disease separately to aligning care with what matters most to …

This trial tests whether a newer ultrasound-guided nerve block, called retro-SCTLB, provides better pain relief after minimally invasive lung cancer surgery than the standard thoracic paravertebral block. Adults aged 18-80 scheduled for thoracoscopic lung cancer removal will be r…

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

This pilot study tests whether a personalized exercise program is practical for 20 adults with stage II or III non-small cell lung cancer who are about to start treatment. Participants will follow the Precise Exercise Regimen for Cancer Care (PERCC) program before and after their…

This trial tests whether changing how the arms are positioned during lung surgery can prevent shoulder pain on the operated side. Shoulder pain is common after thoracoscopic lobectomy, affecting up to 58% of patients, and can hinder recovery. The study will enroll 270 adults sche…

This study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This early-stage study tests an inhaled drug called GDC-6988 in people with lung conditions that cause thick mucus, like non-CF bronchiectasis and COPD. The main goal is to check if the drug is safe and tolerable. About 128 adults with stable disease and good lung function will t…

This study is testing a stress management program designed for people with lung cancer who are waiting for routine scan results. The program includes a short orientation, self-guided web modules with stress management exercises, and coaching calls. Researchers want to see if the …

This study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…

This study looks at whether problems with how the stomach and esophagus move increase the risk of aspiration (food or liquid going into the lungs) in children with brain-related disabilities. It compares two drugs, prucalopride and famotidine, to see which better reduces symptoms…

This registry study is tracking 150 adults with severe emphysema who receive the Spiration Valve System, a one-way valve placed in the lung via a bronchoscope. The goal is to see if the device safely reduces shortness of breath and lung overinflation over 12 to 36 months. Partici…

This study tests a lightweight, battery-powered device called MoblO2 that automatically adjusts oxygen flow to keep blood oxygen levels steady during activity. It is designed for people with COPD or interstitial lung disease who need supplemental oxygen when exerting themselves. …

This study tests a nurse-led support model (ICSM) for family caregivers of older adults newly diagnosed with advanced non-small cell lung cancer. The program includes education, counseling, symptom management, and a web-based resource platform. Researchers will measure whether it…

This study tests whether special hairstyling methods — like braids, cornrows, or a conditioner-and-water mix — can help scalp cooling caps work better to prevent hair loss during chemotherapy. It focuses on people with curly or kinky hair (types 3 and 4), who have been underrepre…

This study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…

This study looks at proteins in lung fluid from 750 people with pneumonia to find biomarkers that could reveal what's causing the lung inflammation. Participants undergo a standard bronchoscopy with lung washings, plus a blood draw. The goal is to better understand different type…

This study is a disease registry that will follow about 700 people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. Researchers will collect information on patient characteristics, treatments, and outcomes over time to better un…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This natural history study follows 270 adults with pulmonary arterial hypertension (PAH) and healthy volunteers to track how the disease changes over time. Researchers will use blood tests, heart and lung imaging, and a six-minute walk test to find new markers of disease severity…

This study tests a special method of removing the breathing tube after abdominal surgery to prevent lung problems. It involves 270 adults at moderate or high risk of lung complications. The goal is to see if a protective extubation approach is practical and followed correctly by …

This study interviews 40 young adults aged 18-30 who use both tobacco (cigarettes or vaping) and cannabis at least weekly. Researchers want to learn how and why people start, increase, and keep using both substances together. The goal is to better understand these behaviors, not …

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study follows up to 3,500 people with sickle cell disease to learn more about how the condition progresses and what complications arise. Participants receive their usual medical care outside the hospital and visit the clinic for check-ups and research tests. No experimental …

This study aims to build a digital early-warning system that uses machine learning to predict acute lung injury (ALI) in patients undergoing major liver surgery. By analyzing cardiopulmonary interaction characteristics, the model could help doctors identify at-risk patients early…

This study looks at whether fungi moving from the gut into the blood can cause inflammation and worsen lung function in people with HIV. Researchers will measure a fungal marker called BDG in blood and urine, and track lung health over three years. The goal is to better understan…

This study looks at factors that might increase the risk of lung cancer in women aged 40 to 74 who have never smoked. Researchers will collect questionnaires and blood samples from 500 women—some with lung cancer and some without—to analyze genetic and exposure-related clues. The…

This study will check 1,000 smokers aged 40+ who visit heart doctors to see how many have undiagnosed COPD, a lung disease that often goes unnoticed. Participants will take a simple breathing test and answer a questionnaire. The goal is to find out how common hidden COPD is in th…

This observational study will follow about 2,000 patients in China who have early-stage lung cancer with a specific gene mutation (EGFR) and have received targeted therapy pills (EGFR-TKIs) after surgery. Researchers will track how long patients live and how long they stay cancer…

This study tests whether briefly increasing the air pressure from a CPAP machine before giving surfactant therapy helps preterm babies' lungs work better. Surfactant is a natural substance that helps immature lungs stay open, and it's often given through a thin tube. The trial wi…

This study looks at the best times to send messages that encourage physical activity to older cancer survivors (65+) who have chronic pain. About 50 participants will wear an activity tracker and rate their pain four times a day using a smartphone app. The goal is to see if certa…

This study will follow 693 people in Brazil with severe or very severe COPD to track how often they are hospitalized, have flare-ups, or die. Researchers want to understand the real-world impact of the disease in this group. No new treatments are being tested—only data is collect…

This study looks at whether a special type of X-ray, called dynamic chest radiography, can help doctors better understand and predict the course of chronic obstructive pulmonary disease (COPD). Researchers will review medical records from about 2,500 people aged 30 to 85 who had …

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it works for people with stage II-III lung cancer before surgery. About 156 participants will receive standard treatment plus immunotherapy at different times of day. The goal is to see…

This early-phase trial will test a new PET imaging agent called 64Cu-DOTA-pembrolizumab in 6 people with stage IV non-small cell lung cancer who are already on the immunotherapy drug pembrolizumab. The goal is to see if the imaging agent can safely tell the difference between tum…

This study looks at whether a campaign called Pink & Pearl can increase lung cancer screening among women who are already getting mammograms. Researchers will track how many eligible women get screened and what factors help or hinder the process. About 279 women aged 50-80 with a…

This study will test 60 adults with bronchiectasis (a chronic lung condition) to see if they have an undiagnosed genetic disorder called primary ciliary dyskinesia (PCD). Researchers will measure nitric oxide in the nose and examine tiny hair-like cells from a nasal swab under a …

This study uses an online questionnaire to understand how side effects from antifibrotic medications affect the emotional and social well-being of patients with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) in Japan. Researchers will ask about patien…

This registry is following 3,000 adults with idiopathic pulmonary fibrosis (IPF) or other chronic fibrosing interstitial lung diseases (ILDs) to understand how these conditions progress over time. Researchers collect information on symptoms, treatments, quality of life, and store…

This early-stage study is testing an inhaled drug called RB042 for the first time in humans. Researchers want to see if it is safe and how the body handles it. The study includes 90 healthy adults, some of whom are smokers. Participants will receive either RB042 or a placebo thro…

This study analyzes tumor tissue from 797 people with relapsed small cell lung cancer to identify genetic subtypes. No drugs are tested here. Instead, the results may help match patients to future targeted therapy trials. Participants must have had prior platinum-based chemothera…

This study tests whether two types of PET/CT scans can show inflammation and scarring in the lungs of people with idiopathic pulmonary fibrosis (IPF). Ten adults aged 40-85 with IPF will receive the scans. The goal is to help doctors better understand the disease and guide future…

This observational study is following about 2,400 adults with non-small cell lung cancer or breast cancer to see how biomarkers, including whole-genome sequencing, relate to their outcomes. Participants receive their usual cancer care, and researchers track progression-free survi…

This study looks at medical records of 3000 people in China with early-stage non-small cell lung cancer (stages I to III). The goal is to understand what treatments patients receive, how often biomarker testing is done, and what happens to them over time. No new treatments are gi…

This study tests a decision-making support program based on restorative justice principles, designed specifically for Black adults who are at high risk for lung cancer. The goal is to see if this approach increases understanding, trust, and willingness to get screened. Forty-five…

This study looks at whether a campaign called Pink & Pearl can help more women get screened for lung cancer. About 5,500 women aged 50-80 who get mammograms at Christian Hospital will take part. Researchers will track how many complete lung cancer screening and how long it takes,…

This study looks at whether genetic markers in tumor tissue, blood, and stool can predict how well lung cancer patients respond to immunotherapy. Researchers will analyze samples from 2,000 adults with lung cancer who are receiving immune checkpoint inhibitors, searching for patt…

This study observes 600 adult patients after major surgery to see if simple bedside tests—like ultrasound of breathing muscles and a breathing score—can predict who will need a breathing tube again. No new treatments are given; doctors make all decisions as usual. The goal is to …

This study surveys doctors who use the Liberant system to remove fresh blood clots from leg arteries and veins. About 50 patients aged 22 or older will be treated within 72 hours of their procedure. The goal is to confirm the device is safe and works as intended.

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study tracks 150 people with non-small cell lung cancer who are getting chemotherapy and radiation followed by immunotherapy. Researchers collect blood, saliva, stool, and lung fluid samples, along with regular lung function tests, to find early signs of lung inflammation (p…

This study aims to find out how often rhinovirus (the virus behind many common colds) causes serious breathing problems that require hospital care in children. Researchers will follow 120 young children at home for 3 years and study 450 hospitalized infants and children, plus 100…

This study aims to understand how lymphangioleiomyomatosis (LAM) damages the lungs at the cellular and genetic level. Researchers will follow up to 2,000 participants, including women with LAM and healthy volunteers, using advanced imaging and lab tests. The goal is to find the p…

This study is testing a new type of MRI that uses xenon gas to see how well the lungs are working in people who have had a bone marrow transplant. Researchers will scan 25 transplant patients with or without lung problems, plus 10 healthy volunteers. The goal is to see if this MR…

This study will test a home-monitoring software called RespirAI in 30 adults with COPD who are at high risk for flare-ups. The app uses artificial intelligence to analyze health data and predict when a serious breathing attack might happen. Researchers will compare the app's pred…

This study is collecting information from 650 people with advanced lung cancer to create 'control arms' — groups that help researchers compare how well new treatments work. Participants will receive standard therapies, and their outcomes will be tracked. The goal is to make futur…

This study looks at how the cancer drug pralsetinib (Gavreto) affects the way the body breaks down other drugs and hormones. Researchers will give a cocktail of common medications and a hormone-based contraceptive to people with advanced solid tumors, then measure how pralsetinib…

This study tests whether it is possible to run a larger trial comparing two ways of using a breathing machine (ventilator) in critically ill heart patients who need help breathing. The two modes are volume-controlled (delivers a set amount of air each breath) and pressure-control…

This study aims to understand cancer-related fatigue in people with non-small cell lung cancer who are receiving immunotherapy. Researchers will interview 20 patients about their fatigue, daily function, and views on physical activity. The goal is to learn how fatigue affects pat…

This study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

This study is a registry that will follow 600 people with early-stage lung cancer who undergo a surgery called segmentectomy. Participants will fill out questionnaires about their health before surgery, shortly after, and six months later. The goal is to measure how long people l…

This study looks at two different approaches to deciding when to place a breathing tube in patients with acute hypoxemic respiratory failure (dangerously low oxygen levels). One strategy is more liberal (intubate earlier to prevent complications from low oxygen), while the other …

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study aims to learn more about Hermansky-Pudlak Syndrome (HPS), a rare inherited disease that causes light skin/eye color, bleeding problems, and often deadly lung scarring. Researchers will follow 600 people with HPS and their family members to track how the disease progres…

This study looks at how PET/CT scans change during chemoimmunotherapy and radiation for stage IV non-small cell lung cancer. Researchers want to see if these scans can help predict how well the cancer responds to treatment. About 80 participants will undergo standard treatment al…

This study investigates whether measuring the physical effort of breathing in children with acute respiratory distress syndrome (ARDS) can predict how the disease will progress. Researchers will use advanced, non-invasive monitoring tools to track breathing drive, effort, and lun…

This study collects blood, tumor, and other tissue samples from up to 1,250 people with head and neck, lung, or gastrointestinal cancers. Researchers want to understand how the immune system changes during cancer treatments, especially immunotherapies. Participants donate samples…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This phase 1 trial is testing a single dose of the investigational drug AMG 691 in healthy Chinese and Japanese adults aged 18 to 60. The goal is to understand how the drug moves through the body and to check its safety and tolerability. Participants will receive one subcutaneous…

This study looks at whether a clear liquid diet for 24 hours before anesthesia can reduce leftover stomach contents in patients taking GLP-1 drugs (like Ozempic). These drugs slow digestion, which can increase the risk of food or liquid entering the lungs during anesthesia. The s…

This study is observing how well the Ion endoluminal system, a robotic tool, works for lung nodule biopsies and localization in everyday medical practice across Europe. Researchers will track 1,200 adults to see how often the tool correctly diagnoses lung nodules and how often co…

This study looks at children aged 1 month to 6 years who are hospitalized with a severe respiratory infection caused by adenovirus or rhinovirus. The goal is to compare the airway cells of those who develop a rare lung condition called post-infectious bronchiolitis obliterans (PI…

This study looks at how lying on your left side, right side, or back affects lung function in adults with acute respiratory distress syndrome (ARDS) after abdominal surgery. Researchers will use a special imaging technique called electrical impedance tomography to measure how wel…

This study is collecting blood samples and health data from 15,000 symptom-free adults over 40 to understand what healthy aging looks like at the molecular level. By tracking participants over time, researchers hope to establish normal ranges for thousands of blood markers and id…

This study looks at the quality of life, symptom severity, and care needs of lung cancer patients who are receiving or have received immunotherapy. By analyzing questionnaires from 180 participants, researchers aim to identify factors that influence these needs, such as marital s…

This study looks at why some older adults with serious conditions like cancer or fractures become vulnerable or frail. Researchers will follow about 1500 patients to find out how common different causes of vulnerability are and how they affect outcomes like survival and quality o…

This trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…

This study is testing whether regular heart and lung monitoring, along with blood samples, can predict side effects in people with lung cancer receiving radiation and immunotherapy. The goal is to find early warning signs of heart or lung damage before symptoms appear. The trial …

General anesthesia bypasses the nose's natural warming and moistening of air, letting cold, dry gases reach the lungs. This study compares two humidification methods—active heated humidification versus a passive heat-moisture exchanger—in adults undergoing video-assisted thoracos…

This study compares three ways to image the lungs of infants: CT scans, electrical impedance tomography (EIT), and lung ultrasound. The goal is to see how well the non-invasive methods (EIT and ultrasound) match up with CT in detecting collapsed or overinflated lung areas. Ten in…

This study compares oxygen readings taken from the finger and the earlobe during a six-minute walk test in people with interstitial lung disease. The goal is to see if one location gives more accurate measurements of oxygen levels during exercise. The results could help doctors d…

This study investigates why breathing muscles weaken in people with end-stage COPD, a severe lung disease. Researchers will measure muscle function using non-invasive tests like ultrasound and EMG, and analyze muscle tissue samples taken during lung transplant surgery. The goal i…

This study aims to create a prediction tool for people with emphysema caused by alpha-1-antitrypsin deficiency, a rare genetic disorder. Researchers will analyze clinical data, lab results, and lung CT scans from 230 patients to identify those at highest risk of death or needing …

This study looks for biological markers in the blood that could help diagnose and predict the course of three serious lung conditions: COPD, idiopathic pulmonary fibrosis (IPF), and lung cancer. Researchers will analyze blood samples from 120 adults with these diseases to find li…

This study looks at how two different exercise styles—steady moderate cycling versus short, intense bursts—affect brain oxygen levels, breathing, and heart function in people with COPD. Researchers will measure changes in brain oxygenation and other body responses during rest, ex…

This study tests a web-based decision-support tool designed to help families and doctors make shared decisions about whether a child should go on chronic home ventilation. Half of the participating families use the tool, while the other half receive usual care. Researchers then m…

This study looks back at medical records of people in Colombia diagnosed with early-stage non-small cell lung cancer between 2017 and 2023. Researchers aim to understand how patients are diagnosed, how long it takes to start treatment, and what factors affect their care. By mappi…